ERIBULIN MESYLATE
Generic: ERIBULIN MESYLATE
BluePoint LaboratoriesManufacturer
INTRAVENOUSRoute
ERIBULIN MESYLATEActive Substance
2024-07-18Original Approval
ERIBULIN MESYLATE is FDA application ANDA214850, sponsored by LONG GROVE PHARMS. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Top Reported Reactions
1
NEUROPATHY PERIPHERAL
62 reports
2
MALIGNANT NEOPLASM PROGRESSION
55 reports
3
MYELOSUPPRESSION
51 reports
4
PYREXIA
50 reports
5
FATIGUE
42 reports
6
NEUTROPENIA
40 reports
7
OFF LABEL USE
40 reports
8
NAUSEA
36 reports
9
DIARRHOEA
33 reports
10
HEADACHE
30 reports